Dual checkpoint blockade for melanoma brain metastases: durable response at a toxicity cost

Design

Systematic review and meta-analysis of 24 prospective and retrospective studies

Population

3,518 adults with melanoma brain metastases on dual checkpoint inhibition

Primary outcome

Intracranial progression-free survival, overall survival, response

Effect

Intracranial response 42.5%; 1-year intracranial PFS 44.1%; grade ≥3 toxicity 48.2%

A systematic review pooled 24 prospective and retrospective studies of 3,518 adults with melanoma brain metastases treated with dual immune checkpoint inhibition, mostly nivolumab with ipilimumab.

Pooled intracranial response was 42.5% (48% when used first line). Intracranial progression-free survival was 51.9% at six months, 44.1% at one year and 38.8% at three years. Three-year overall survival was 52.3% in asymptomatic patients and 31.5% in symptomatic ones. Overall survival favoured dual over single-agent therapy at six months, one and two years, but not significantly at three. Grade 3 or higher treatment-related adverse events occurred in 48.2%.

This supports the current approach of offering combination therapy early, particularly before brain metastases cause symptoms. It also underlines why symptomatic disease remains hard to treat and why toxicity monitoring needs to be organised before the first dose.

For dermatologists, the practical link is surveillance: in high-risk melanoma, brain imaging that finds asymptomatic metastases may open the better-performing route.

• Discuss brain imaging in staging and follow-up of high-risk melanoma with the oncology team.
• Refer asymptomatic brain metastases promptly; outcomes were better before symptoms developed.
• Prepare patients for a roughly one-in-two chance of severe immune-related toxicity on combination therapy.
• Raised LDH was linked to worse survival; BRAF status was not.

Why it matters

Brain metastases found before symptoms appear did considerably better, which shifts weight onto surveillance.

Don't overread it

Most included studies were retrospective, and the three-year advantage over monotherapy was not shown.

The statistics, in plain English

An intracranial response of 42.5% means the brain lesions shrank meaningfully in about four in ten patients. Comparisons with monotherapy come from non-randomised studies, so sicker patients may have received single agents. Pooling across differing studies adds heterogeneity, which the authors flag for the three-year results.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.